Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00047008 · OUTCOME

Head and Neck Radiotherapy Questionnaire (HNRQ) - AUC at One Year

Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer · Source last updated 2023-07-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
score on a scale * months
Interval / dispersion
Standard Error
Time frame
Baseline (pretreatment), sometime during the last two weeks of treatment, three months from start of treatment, and one year from start of treatment.

What was measured

The HNRQ is a patient-reported questionnaire administrated through a paper format; it measures radiation-related side effects and the overall well-being of head and neck cancer patients in the past week. The overall score is the mean of the 22 questions, with a range of 1 to 7. Higher scores indicate better quality of life. Treatment effect was analyzed as time-weighted average between baseline (pre-treatment) and 1 year calculated by use of area under the curve (AUC).

Analysis population: Eligible participants who did not withdraw consent, with all 4 assessments: baseline, last 2 weeks of treatment, 3 months, and one year.

Groups in this outcome

Standard Fractionation RT + Cisplatin

Standard fractionation radiation therapy with concurrent cisplatin followed by conventional surgery for select patients.

Accelerated Fractionation RT + Cisplatin

Accelerated fractionation radiation therapy by concomitant boost with concurrent cisplatin followed by conventional surgery for select patients.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Standard Fractionation RT + Cisplatin139
Accelerated Fractionation RT + Cisplatin137

Reported measurements

Source class 1
Values in score on a scale * months · Interval/dispersion: Standard Error
GroupValueSpreadLowerUpperComment
Standard Fractionation RT + Cisplatin5.270.07Not reportedNot reportedNot reported
Accelerated Fractionation RT + Cisplatin5.190.07Not reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. group Description
    Two hundred and fifty-two patients (126/arm) provide at least 86% power to detect a difference of 7 (standard deviation 18) between arms with a two-sided significance level of 0.05.
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.39
    p Value Comment
    Two-sided significance level = 0.05
    statistical Method
    t-test, 2 sided
Complete source fields
analyses
  1. group Description
    Two hundred and fifty-two patients (126/arm) provide at least 86% power to detect a difference of 7 (standard deviation 18) between arms with a two-sided significance level of 0.05.
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.39
    p Value Comment
    Two-sided significance level = 0.05
    statistical Method
    t-test, 2 sided
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.07
        value
        5.27
      2. group Id
        OG001
        spread
        0.07
        value
        5.19
denoms
  1. counts
    1. group Id
      OG000
      value
      139
    2. group Id
      OG001
      value
      137
    units
    Participants
description
The HNRQ is a patient-reported questionnaire administrated through a paper format; it measures radiation-related side effects and the overall well-being of head and neck cancer patients in the past week. The overall score is the mean of the 22 questions, with a range of 1 to 7. Higher scores indicate better quality of life. Treatment effect was analyzed as time-weighted average between baseline (pre-treatment) and 1 year calculated by use of area under the curve (AUC).
dispersion Type
Standard Error
groups
  1. description
    Standard fractionation radiation therapy with concurrent cisplatin followed by conventional surgery for select patients.
    id
    OG000
    title
    Standard Fractionation RT + Cisplatin
  2. description
    Accelerated fractionation radiation therapy by concomitant boost with concurrent cisplatin followed by conventional surgery for select patients.
    id
    OG001
    title
    Accelerated Fractionation RT + Cisplatin
param Type
MEAN
population Description
Eligible participants who did not withdraw consent, with all 4 assessments: baseline, last 2 weeks of treatment, 3 months, and one year.
reporting Status
POSTED
time Frame
Baseline (pretreatment), sometime during the last two weeks of treatment, three months from start of treatment, and one year from start of treatment.
title
Head and Neck Radiotherapy Questionnaire (HNRQ) - AUC at One Year
type
SECONDARY
unit Of Measure
score on a scale * months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice